• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

NEW GLOBOCAN STATISTICS PLACED LUNG CANCER AS THE MOST FREQUENT CANCER AND THE LEADING CAUSE OF CANCER DEATH AMONG MALES

According to tthe new statistics, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6 % of […]

#WCLC2018 CONCLUSIONS – STRATEGIES TO MAXIMIZE THE CLINICAL BENEFIT OF EGFR TKIS IN ADVANCED NSCLC

During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC. Apply expert […]

#WCLC2018 CONCLUSIONS – NELSON STUDY SHOWS CT SCREENING FOR NODULE VOLUME MANAGEMENT REDUCES LUNG CANCER MORTALITY BY 26 PERCENT IN MEN

During the World Congress on Lung Cancer held this year in Toronto, Canada were presented the findings of NELSON study. […]

LUNG CANCER EUROPE IS GROWING STRONGER

Starting September, Alfonso Aguarón (second from left) is LuCE’s new project manager. He has extensive experience in patient advocacy field […]

NEW ESMO TUMOUR DNA SCALE HELPS MATCH PATIENTS WITH CANCER TO OPTIMAL TARGETED MEDICINES

A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by […]

THE SOCIETY FOR IMMUNOTHERAPY OF CANCER CONSENSUS STATEMENT ON IMMUNOTHERAPY FOR THE TREATMENT OF NSCLC

Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the […]